Abstract

Background: Colorectal cancers (CRC) with brain metastases (BM) are scarcely described. The main objective of this study was to determine the molecular profile of CRC with BM. Methods: We included 82 CRC patients with BM. KRAS, NRAS, BRAF and mismatch repair (MMR) status were investigated on primary tumors (n = 82) and BM (n = 38). ALK, ROS1, cMET, HER-2, PD-1, PD-L1, CD3 and CD8 status were evaluated by immunohistochemistry, and when recommended, by fluorescence in situ hybridization. Results: In primary tumors, KRAS, NRAS and BRAF mutations were observed in 56%, 6%, and 6% of cases, respectively. No ROS1, ALK and cMET rearrangement was detected. Only one tumor presented HER-2 amplification. Molecular profiles were mostly concordant between BM and paired primary tumors, except for 9% of discordances for RAS mutation. CD3, CD8, PD-1 and PD-L1 expressions presented some discordance between primary tumors and BM. In multivariate analysis, multiple BM, lung metastases and PD-L1+ tumor were predictive of poor overall survival. Conclusions: CRCs with BM are associated with high frequency of RAS mutations and significant discordance for RAS mutational status between BM and paired primary tumors. Multiple BM, lung metastases and PD-L1+ have been identified as prognostic factors and can guide therapeutic decisions for CRC patients with BM.

Highlights

  • Brain metastases (BM) from colorectal cancer (CRC) are rare with an incidence ranging from 0.6 to3.2% and are associated with a poor prognosis with an overall survival (OS) of about 5.0 months [1,2].Patients with brain metastases (BM) from Colorectal cancers (CRC) present a specific clinical profile with predominant rectosigmoid primaryCancers 2018, 10, 504; doi:10.3390/cancers10120504 www.mdpi.com/journal/cancersCancers 2018, 10, 504 tumor location and lung metastases [3,4,5,6]

  • Our study provided relevant and specific features of CRC patients with BM, such as frequent lung metastasis, frequent rectal tumor site and high rate of RAS mutation

  • These results suggest a need for BM screening in this metastatic CRC (mCRC) patients subgroup, but will require further prospective investigations to determine if early identification of BM improves survival and/or quality of life

Read more

Summary

Introduction

Cancers 2018, 10, 504 tumor location and lung metastases [3,4,5,6]. Some small series have suggested a high rate of KRAS mutation in CRC with BM, but no study has evaluated complete RAS (KRAS and NRAS), BRAF and mismatch repair (MMR) status [1]. In metastatic CRC (mCRC), molecular profiles of liver and lung metastases have already been tested and revealed a high concordance between the metastases and paired primary tumor (PPT). KRAS, NRAS, BRAF and mismatch repair (MMR) status were investigated on primary tumors (n = 82) and BM (n = 38). Results: In primary tumors, KRAS, NRAS and BRAF mutations were observed in 56%, 6%, and 6% of cases, respectively. Molecular profiles were mostly concordant between BM and paired primary tumors, except for 9% of discordances for RAS mutation

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call